Document Detail


Long-term levetiracetam treatment of epilepsy patients: clinical audit.
MedLine Citation:
PMID:  16930945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The long-term efficacy and tolerability of levetiracetam (LEV) was analysed in 218 epilepsy patients. One hundred and ninety-nine patients were treated for at least 6 months. We evaluated LEV efficacy for all types of seizures together, and for simple partial, complex partial and secondary generalized seizures individually. RESULTS: A significant decrease in the number of seizures occurred after 6 months of treatment (p<0.001). Mean seizure frequency (irrespective of type) before LEV was 19.2 a month. The mean monthly frequency at 6, 12, 24 and 36 months dropped to 12.7, 10.5, 9.7 and 7.1 seizures a month, respectively. The mean percentage reduction in seizures at these times was 45.7, 52.1, 59.1 and 64.2% and the number of responding patients was 51.3, 54.2, 59.8 and 62.2%. The number of patients completely seizure free was 18.6, 16.7, 15.2 and 16.2%. We found similar results in the last three categories for partial simple, complex and secondary generalized seizures individually. Side effects in 18.3% of patients caused treatment discontinuation in 6.4%. The most frequent were somnolence, moodiness and dizziness. The retention rate at 6, 12, 24 and 36 months was 0.848, 0.72, 0.62 and 0.5, respectively. CONCLUSIONS: LEV is effective and well tolerated for long-term treatment of epilepsy.
Authors:
R Kuba; I Novotná; M Brázdil; J Kocvarová; I Tyrliková; J Mastík; I Rektor
Related Documents :
10706025 - Neuro-cognitive development and epilepsy outcome in children with surgically treated he...
12767495 - Treatment of status epilepticus: a survey of neurologists.
11903465 - Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain...
1707795 - A comparison between electroencephalography and somatosensory evoked potentials for out...
9632055 - The detoxification experience of alcoholic in-patients and predictors of outcome.
23705945 - The risk of early mortality of polytrauma patients associated to iss, niss, apache ii v...
Publication Detail:
Type:  Evaluation Studies; Journal Article     Date:  2006-08-22
Journal Detail:
Title:  Epilepsy research     Volume:  72     ISSN:  0920-1211     ISO Abbreviation:  Epilepsy Res.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-12     Completed Date:  2007-03-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  111-9     Citation Subset:  IM    
Affiliation:
Epilepsy Centre; Department of Neurology, Masaryk University, St. Anne's Teaching Hospital, Brno, Czech Republic. robert.kuba@fnusa.cz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticonvulsants / administration & dosage,  adverse effects,  therapeutic use*
Chi-Square Distribution
Drug Therapy, Combination
Epilepsy / drug therapy*
Humans
Kaplan-Meiers Estimate
Piracetam / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Retrospective Studies
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/Anticonvulsants; 33996-58-6/etiracetam; 7491-74-9/Piracetam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Attention and psychomotor speed decline in patients with temporal lobe epilepsy: a longitudinal stud...
Next Document:  Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that...